Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

NCT04042298
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions
Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw
Other
Lead sponsor
Kansas State University
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Fundoplication in Laparoscopic PEH Repair Based on FLIP

NCT05807763
Conditions
Paraesophageal Hernia
Interventions
Laparoscopic paraesophageal hernia repair without fundoplication
Procedure
Lead sponsor
The Foundation for Surgical Innovation and Education
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Evanston, Illinois • Portland, Oregon
Conditions
Cystic Fibrosis
Interventions
Sildenafil 40mg oral capsule, Placebo Oral capsule
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
9 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Colorectal Neoplasms
Interventions
Yoga, Physical Activity
Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Liver Cancer
Interventions
Resveratrol, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Inflammatory Bowel Diseases
Interventions
Biofeedback Enhanced Treatment
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
AV608
Drug
Lead sponsor
Avera Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Not listed No phase listed Observational

Genetics of Fibromyalgia

NCT00071162
Conditions
Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome, Depression
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
12 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
4
States / cities
Peoria, Illinois • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Conditions
Postoperative Ileus, Postoperative Nausea, Postoperative Complications, Postoperative Nausea and Vomiting, Postoperative Vomiting, Aspiration Vomitus
Interventions
Bedside gastric ultrasound
Diagnostic Test
Lead sponsor
Eric Schwenk
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Naturopathic medicine
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Fuco-N-Tetraose
Other
Lead sponsor
Glycom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Conditions
Obesity, High Blood Pressure, High Cholesterol, Type2 Diabetes, Heart Diseases
Interventions
Curcumin
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Drug · Combination Product
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Conditions
IBS (Irritable Bowel Syndrome), Diarrhea
Interventions
MITI-001 administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Dublin, California • Fremont, California • Fresno, California + 15 more
Conditions
Sphincter of Oddi Dysfunction
Interventions
Duloxetine
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions
Discontinuation of Pancreatic Enzyme Replacement Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
0 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed No phase listed Observational Accepts healthy volunteers

Genetic Contribution of Pain and Inflammation in IBS

NCT01436760
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Terminated Phase 2 Interventional Results available

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

NCT01471379
Conditions
Irritable Bowel Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Spencer Dorn, MD, MPH
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina